Notícias

PFE is betting on monthly obesity treatments and new oral programs to challenge LLY and NVO in a market projected to hit $120 billion by 2035.

Wegovy pill's U.K. approval gives Novo Nordisk its first European launch path ahead of wider EU approval as it seeks growth amid mounting pricing and competitive pressures.

Novo Nordisk (NYSE:NVO) is seeing strong uptake of its oral Wegovy treatment, with the tablet formulation accounting for roughly one-third of all Wegovy prescriptions by May, according to a Bank of America report published on Thursday. The data highlights the rapid adoption of the oral version since its market debut earlier this year and underscores continued momentum across the broader GLP-1 weight-loss drug market.

Barclays expects accelerating revenue and EBITDA growth in the second half of 2026, supported by weight-loss offerings.

Johnson & Johnson has no plans to enter the booming obesity market, opting instead to focus on diseases such as cancer, CEO Joaquin Duato said in an interview for an upcoming episode of The David Rubenstein Show: Peer to Peer Conversations. The comments set J&J apart from many of its rivals that are trying to develop or acquire obesity medicines following blockbuster weight-loss drugs from Eli Lilly & Co. and Novo Nordisk.

Healthcare stocks declined late Wednesday afternoon, with the NYSE Healthcare Index falling 1.3% and

Johnson & Johnson is focusing on oncology and neuroscience instead of obesity drugs, with AI possibly supporting its next growth cycle.

European stock markets closed mostly higher Wednesday as the Stoxx Europe 600 gained 0.5%, the Swiss

The group says it spent more than two months inside Novo Nordisk's networks, stealing over a terabyte of data including proprietary drug and AI information

Novo Nordisk (NYSE:NVO) has disclosed a patient data breach affecting individuals involved in its clinical trials. The company is assessing the scope of the data exposure and potential regulatory implications. At the same time, Novo Nordisk continues to face production capacity constraints for its GLP-1 therapies, including obesity treatment Wegovy. The combination of data security concerns and supply limitations raises fresh questions about operational resilience for the drug maker. Novo...

Novo Nordisk (CPSE:NOVO B) plans to seek Chinese regulatory approval for its oral Wegovy obesity pill. The planned filing would extend the company's weight loss franchise into China, a large potential market for obesity therapies. This move comes after prior focus on injectable Wegovy and recent attention on regulatory milestones in other regions, including the UK. Novo Nordisk, best known for its diabetes and obesity treatments, is pushing further into weight management with the oral...

CEO Doustdar expects to submit oral Wegovy for Chinese regulatory approval in "a few months"

Healthcare stocks edged higher Tuesday afternoon, with the NYSE Healthcare Index and the State Stree

These two healthcare leaders have a long history of competing against one another.

The European stock markets were modestly higher in Tuesday trading as the markets reacted positively

Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

The move could expand Novo's reach in a key obesity-drug market.

Stocktwits data showed retail sentiment on SPY and QQQ has remained ‘bearish’ despite the recent rally.

Novo Nordisk (NVO) plans to apply for Chinese regulatory approval of its oral weight-loss drug, Wego

In April, the stock faced resistance near $30 and saw selling pressure in the following weeks.

NVO stock jumps 7% in a week on U.K. approval of oral Wegovy and positive commercial updates, but competition and 2026 pressure cloud near-term outlook.

PFE trades at a steep discount as COVID sales fade and patent cliffs loom, but new products, oncology strength and pipeline plans could shape its future.

Novo Nordisk (NVO) has spent 2026 trying to convince investors that the worst is behind it. After a punishing year, the stock is finally clawing back from its lows. So, when Goldman Sachs sat down with management at a major healthcare conference this month, investors wondered if the bank would turn ...

Eli Lilly is winning the GLP-1 race right now, but it isn't resting on its laurels.

Novo Nordisk (NYSE:NVO) has received first-in-Europe approval in the UK for its daily oral Wegovy pill for chronic weight management. The decision introduces a non injectable GLP-1 option for obesity treatment in the UK market. The company plans to launch the oral Wegovy pill in additional international markets later in 2026. Novo Nordisk, trading at $43.88, is adding another product to its obesity portfolio with this UK approval of oral Wegovy. The stock is up 2.1% over the past week,...

The National Bureau of Economic Research paper's lead author hopes putting a dollar value on the benefits of GLP-1s will lead to better access

Novo Nordisk has received UK approval for its Wegovy pill, the first daily oral GLP-1 weight-loss treatment licensed in Europe. The decision follows recent launches of the oral Wegovy treatment in the US and UAE. Phase 3 and real-world data indicate weight loss outcomes comparable to injectable GLP-1 products, with a safety profile regulators consider acceptable for broader use. For investors tracking CPSE:NOVO B, this approval comes at a time when the share price is around DKK287.25 and...

Healthcare has spent 2026 on the sidelines while the rest of the market does the heavy lifting. The Health Care Select Sector SPDR Fund (NYSEARCA:XLV) is down around 1% year to date even after a 6% one-month bounce. That stagnation has left a handful of high-margin operators trading at forward multiples that look out of ... 3 Ridiculously Cheap Healthcare Stocks to Buy in June

Novo Nordisk A/S (NYSE:NVO) is one of the 7 Best Longevity Stocks to Buy Now. On June 7, 2026, Novo Nordisk A/S (NYSE:NVO) presented Phase 3 results from its Reimagine 1-3 trials, which showed significant reductions in HbA1c and weight in adults with type 2 diabetes. The Reimagine trials met their primary endpoints, showing significant […]

Thursday’s unusual options activity had plenty to choose from. However, it was the LEAPS that were really worth considering for bullish investors. Of the 28 calls over 365 days, these three quality stocks stood out.